Which heart stent works best? a large registry aims to find out

NCT ID NCT02038127

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This registry tracks 5,000 people with coronary artery disease who receive one of three drug-eluting stents during angioplasty: Biolimus, Everolimus, or Zotarolimus. Researchers will compare rates of heart-related death, heart attack, and repeat procedures over two years. The goal is to see which stent performs best in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: drug-eluting stents (Biolimus, Everolimus, or Zotarolimus)
What this could lead to: If successful, this registry could help identify which stent type offers the best long-term safety and effectiveness for people with blocked heart arteries.
What could go wrong: This is an observational registry, not a randomized trial, so results may be influenced by patient selection. Stent-related risks include blood clots, heart attack, and need for repeat procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

Chuncheon Hallym University Hospital
NOT_YET_RECRUITING

Chuncheon, Gangwon-do, South Korea
Korea University Guro Hospital
RECRUITING

Seoul, South Korea
Yonsei University Wonju Christian Hospital
RECRUITING

Wŏnju, Gangwon-do, 220768, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.